Daxor Corporation Announces Year End 2004 Earnings.NEW YORK New York, state, United States New York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of -- Daxor Corporation (Amex: DXR DXR Danbury Municipal Airport, Danbury CT (airport code) DXR Data Extraction and Recording DXR X-Director DXR Dynamic Extended Resolution )
TWELVE MONTHS ENDED
December 2004 December 2003
---------------- -----------------
Total Revenues $ 4,230,641 $ 3,165,437
Net Income (loss) $ (580,268) $ (1,076,189)
Weighted Average Number
Of shares outstanding 4,616,076 4,647,350
Equivalent Share
Earnings (loss) per share $ (0.12) $ (0.23)
Daxor Corporation, (AMEX: DXR) a leading medical instrumentation and biotechnology company, today announced the Company had an increase in expenses and operating revenues operating revenue Revenue from any regular source. Revenue from sales is adjusted for discounts and returns when calculating operating revenue. Compare other revenue. . The Company had a loss of 12 cents per share Cents per share The amount of a mutual fund's dividend or capital gains distributions that a shareholder will receive for each share owned. in 2004. This was due to an anticipated increase in expenses as the Company expanded its sales and marketing staff in 2004. Operating revenues from the BVA-100 division, however, increased by 20% in 2004. The Company intends to continue to expand its sales staff as well as increase its presence at trade shows. In the past 3 years, there have been research papers from major medical institutions concerning the benefits of measuring blood volume. The Company produces the BVA-100, the only semi-automated Blood Volume Analyzer approved by the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. . On February 23, 2005, the Company was informed that its auditors of the past 25 years were not PCAOB PCAOB Public Company Accounting Oversight Board registered in accordance with Sarbanes-Oxley. The Company, therefore, retained the services of Rotenberg Meril Solomon Bertiger & Guttilla, P.C. As part of the change in auditors, a repeat audit of the 2003 filings was required. That audit, and 10K, has been completed, with no material change, and submitted. The 2004 10K submission will be filed no later than Tuesday, April 19, 2005. Additional information about the BVA-100 and other medical studies can be found on Daxor's website, www.daxor.com. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion